Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript

Gregory Divis: Richard, do you have any general thoughts on it.

Richard Kim: Sure. Sorry about that, Greg. Yes, in general, no. These are still generally younger patients, less of a Medicare population overall. So a general statement, it would be not really that we see from our data.

Myriam Belghiti: Okay. Got it. Thanks for taking my question.

Operator: Your next question comes from the line of Matt Kaplan with Ladenburg Thalmann. Mr. Kaplan your line is open.

Matthew Kaplan: Good morning. And congrats on the quarterly results. Given your success in terms of adding prior Xywav patients to LUMRYZ, how important is it to have a low sodium offering in the market. And I guess second part of that question is how difficult will it be to create a low sodium bioequivalent rise?

Gregory Divis: Yes. I think our view has been very consistent on this topic from the beginning, which is that we think all patients should have the opportunity to have an uninterrupted night sleep. And for the subset of patients who are at risk for sodium, if we have the ability to formulate and develop and bring that opportunity to the marketplace, then we’re certainly going to do the work to try to accomplish that. So from our perspective, it isn’t a requirement to have a successful once-nightly LUMRYZ franchise, because we do believe that data on sodium speaks for itself. That being said, we certainly know there’s patients out there who could benefit from both a lower sodium version and once at bedtime LUMRYZ. So therefore, we’re doing the work.

In terms of the difficulty of it, it’s a formulation challenge in and of itself, given how the active moiety performs in this sort of situation, but we certainly have our best and brides working with our third-party partners on this, and we look forward to giving you an update later this year.

Matthew Kaplan: All right. Thanks for taking the question.

Gregory Divis: Thanks Matt.

Operator: That concludes our Q&A session. I will now turn the conference back over to Greg Divis for closing remarks.

Gregory Divis: Thank you. And most importantly, thank you everyone for joining us today. Thank you for your time, and we wish you a great day, and we look forward to future updates and any follow-up during the course of today and over the next couple of weeks. Have a great day. Thank you.

Operator: Ladies and gentlemen, that concludes today’s call. Thank you all for joining. You may now disconnect.